Affordable Access

deepdyve-link
Publisher Website

Targeting CD73 to augment cancer immunotherapy.

Authors
  • Roh, Meejeon1
  • Wainwright, Derek A2
  • Wu, Jennifer D3
  • Wan, Yong4
  • Zhang, Bin5
  • 1 Robert H. Lurie Comprehensive Cancer Center, Department of Medicine-Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
  • 2 Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
  • 3 Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
  • 4 Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
  • 5 Robert H. Lurie Comprehensive Cancer Center, Department of Medicine-Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. Electronic address: [email protected]
Type
Published Article
Journal
Current opinion in pharmacology
Publication Date
Aug 07, 2020
Volume
53
Pages
66–76
Identifiers
DOI: 10.1016/j.coph.2020.07.001
PMID: 32777746
Source
Medline
Language
English
License
Unknown

Abstract

CD73 (ecto-5'-nucleotidase) is a novel immunoinhibitory protein that plays a key role for tumor growth and metastasis. Its main function is to convert extracellular ATP to immunosuppressive adenosine in concert with CD39 in normal tissues to limit excessive immune response. However, tumors take advantage of the CD73-mediated adenosinergic mechanism to protect them from immune attack. In particular, inducible expression of CD73 along with other adenosinergic molecules on both cancer cells and host cells sustains immunosuppressive tumor microenvironment by affecting multiple aspects of the immune response. Owing to its multifaceted capacity to tumor promotion as an emerging immune checkpoint, CD73 is an ideal therapeutic target for cancer treatment especially in combination with conventional therapy and/or other immune checkpoint inhibitors. In this review, we will discuss the roles of CD73 on tumor and immune cells and will highlight the therapeutic value of CD73 for combination therapy. Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Report this publication

Statistics

Seen <100 times